Form 4: Collegium Pharmaceutical EVP Scott Dreyer Sells Shares Under 10b5-1 Plan

EVP & Chief Commercial Officer of Collegium Pharmaceutical, Scott Dreyer, sold 15,387 shares of common stock at an average price of $30.004 per share on March 6, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 6, 2025, Scott Dreyer, the EVP & Chief Commercial Officer of Collegium Pharmaceutical, sold 15,387 shares of common stock.
• The sale was executed at a weighted average price of $30.004 per share.
• The transactions occurred within a price range of $30.00 to $30.03.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on August 28, 2024.
• Following the transaction, Dreyer directly owns 126,676 shares of Collegium Pharmaceutical.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports an insider stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

Insider sales are a common occurrence and are often related to personal financial planning rather than a reflection of the company's prospects. The use of a 10b5-1 trading plan suggests the sale was pre-planned.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the use of a 10b5-1 plan mitigates concerns about insider information.

Key Dates